Figure 2.

In silico analysis of MCM2, MCM4, MCM6, and MKI67 mRNA expression as represented by bc-GenExMiner database v3.2

(A and B) Basal-like, HER2-enriched, and luminal B breast cancers show higher expression of MCM2, MCM4, MCM6, and MKI67 mRNA levels in comparison with luminal A (P < .0001), as shown in the boxplots and the heat maps. Notably, there is no overlap between individual boxes in the boxplot when luminal A breast cancers were compared to luminal B breast cancers. (C) Gene expression values were used to define three equal groups (low, intermediate, and high expression) to examine their distribution in the different breast cancer molecular subtypes. The percentage of patients with low, intermediate, and high levels of MCM2, MCM4, MCM6 and MKI67 expression in each molecular subtype of breast cancer is depicted in the tables.